Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials

Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials

The effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to...

Full description

Bibliographic Details
Main Authors: Tarun Krishna Boppana, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, Randeep Guleria
Format: Article
Language:English
Published: PAGEPress Publications 2022-02-01
Series:Monaldi Archives for Chest Disease
Subjects:
Tocilizumab
COVID-19
meta-analysis
interleukin 6
IL-6 inhibitor
SARS CoV-2
Online Access:https://www.monaldi-archives.org/index.php/macd/article/view/2136

Internet

https://www.monaldi-archives.org/index.php/macd/article/view/2136

Similar Items